Alzamend Neuro, Inc. (ALZN)
NASDAQ: ALZN · Real-Time Price · USD
1.130
+0.010 (0.89%)
At close: Oct 23, 2026, 4:00 PM EDT
1.131
+0.001 (0.04%)
After-hours: Oct 23, 2026, 5:32 PM EDT
Alzamend Neuro Market Cap
Alzamend Neuro has a market cap or net worth of $5.45 million as of October 23, 2026. It is the 44,495th most valuable company in the world and the 5,938th biggest in the United States. Its market cap has decreased by 38.70% in one year.
Market Cap
5.45M
Enterprise Value
-2.14M
1-Year Change
-38.70%
Global Rank
Country Rank
#5,938 United States
Category
ChartMarket Cap Chart
Since the IPO on June 15, 2021, Alzamend Neuro's market cap has decreased from $1.15B to $5.45M, a decrease of -99.52%. That is a compound annual growth rate of -63.14%.
| Date | Market Cap | % Change |
|---|---|---|
| Oct 23, 2026 | 5.45M | -21.19% |
| Dec 31, 2025 | 6.92M | 9.79% |
| Dec 31, 2024 | 6.30M | -0.56% |
| Dec 29, 2023 | 6.34M | -88.37% |
| Dec 30, 2022 | 54.47M | -67.73% |
| Dec 31, 2021 | 168.82M | -85.28% |
| Jun 15, 2021 | Upgrade Pro | Upgrade Pro |
Market Capitalization
Market capitalization, also called net worth, is the total value of all of a company's outstanding shares. It is calculated by multiplying the stock price by the number of shares outstanding.
Formula: Market Cap = Stock Price * Shares Outstanding
Related Stocks
| Company | Market Cap |
|---|---|
| Acurx Pharmaceuticals | 5.98M |
| Senti Biosciences Holdings | 5.87M |
| Can-Fite BioPharma | 5.81M |
| Alaunos Therapeutics | 5.79M |
| Evogene | 5.58M |
| Pulmatrix | 5.41M |
| Niki BioSolutions | 5.38M |
| Traws Pharma | 5.26M |